OX-40 Agonist -Pipeline Insights, 2015
Summary
DelveInsight’s, OX-40 AntagonistPipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the OX-40 Antagonist. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The OX-40 AgonistReport helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
DelveInsight’s, OX-40 Antagonist-Pipeline Insights, 2015 Report covers the OX-40 Antagonistpipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides OX-40 Agonistrelated therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for OX-40 Antagonist.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the Mechanism of Action (MoA).
Scope
- DelveInsight’s report provides a OX-40 Agonist Landscape across the globe
- The report provides drug profiles which includes product description, licensors & collaborators, development partner and chemical information
- Coverage of the OX-40 Agonist pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for OX-40 Agonistand also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for OX-40 Antagonist.
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Track your competitors and develop strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
- Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned
Table of Contents
OX-40 AgonistOverview
OX-40 AgonistDisease Associated
OX-40 AgonistPipeline Therapeutics
OX-40 AgonistTherapeutics under Development by Companies
OX-40 AgonistLate Stage Products (Filed and Phase III)
Comparative Analysis
OX-40 AgonistMid Clinical Stage Products (Phase II)
Comparative Analysis
OX-40 Agonist Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis
OX-40 AgonistDiscovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
OX-40 Antagonist– Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
OX-40 Antagonist– Discontinued Products
OX-40 Agonist– Dormant Products
Companies Involved in Therapeutics Development for OX-40 Antagonist
Appendix
Methodology
Contact Us
Disclaimer
List of Tables
Number of Products under Development for OX-40 Agonistby Therapy Area, 2015
Number of Products under Development for OX-40 Antagonist,2015
Number of Products under Development by Companies
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
Drug Candidates Profiles
OX-40 AgonistAssessment by Monotherapy Products
OX-40 AgonistAssessment by Combination Products
OX-40 AgonistAssessment by Route of Administration
OX-40 AgonistAssessment by Stage and Route of Administration
OX-40 AntagonistAssessment by Molecule Type
OX-40 AgonistAssessment by Stage and Molecule Type
OX-40 AgonistTherapeutics – Discontinued Products
OX-40 AgonistTherapeutics – Dormant Products
Products under Development by Companies, 2015
List of Figures
Number of Products under Development for OX-40 Agonistby Therapy Area, 2015
Number of Products under Development for OX-40 Antagonist, 2015
Late Clinical Stage Products (Filed and Phase III), 2015
Mid Clinical Stage Products (Phase II), 2015
Early Clinical Stage Products (Phase I and IND Filed), 2015
Discovery and Pre-Clinical Stage Products, 2015
OX-40 AgonistAssessment by Monotherapy Products
OX-40 Antagonist, Assessment by Combination Products
OX-40 Antagonist, Assessment by Route of Administration
OX-40 Antagonist, Assessment by Stage and Route of Administration
OX-40 Antagonist, Assessment by Molecule Type
OX-40 Antagonist, Assessment by Stage and Molecule Type